Hypertension and ethnic group

British Medical Journal

Volumn 332, Issue 7545, 2006, Pages 835-836

  Brown, Morris J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; PLACEBO; PRAZOSIN; RENIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; VASOCONSTRICTION; AFRICA; AGED; ASIA; BLOOD; ETHNOLOGY; MIDDLE AGED;

ADULT; AFRICA; AGED; ASIA; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RENIN;

EID: 33645800971     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7545.833     Document Type: Article

References (25)

1. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, et al; MRC British genetics of hypertension study. Genome-wide mapping of human loci for essential hypertension. Lancet 2003;361:2118-23.
2. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
3. Mackenzie IS, Brown MJ. Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment. Clin Med 2002;5:465-73.
4. Guyton AC. Kidneys and fluids in pressure regulation: small volume but large pressure changes. Hypertension 1992;19:I2-8.
5. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981;291:329-31.
6. Falkner B. Differences in blacks and whites with essential hypertension: biochemistry and endocrine: state of the art lecture. Hypertension 1990;15:681-6.
7. Luft FC, Grim CE, Fineberg N, Weinberger MC. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 1979;59:643-50.
8. James GD, Sealey JE, Muller F, Alderman M, Madhavan S, Laragh JH. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl 1986;4:S387-9.
9. Fisher ND, Gleason RE, Moore TJ, Williams GH, Hollenherg NK. Regulation of aldosterone secretion in hypertensive blacks. Hypertension 1994;23:379-84.
10. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hyper tension. JAMA 1979;241:151-6.
11. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
12. Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in b subunit of epithelial sodium channels in black people resident in London. Lancet 1998;351:1388-92.
13. Curtin PD. The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 1992;82:1681-6.
14. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens 2003;17:523-34.
15. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart 1997;78:555-63.
16. Raleigh VS, Kiri V, Balarajan R. Variation in mortality from diabetes mellitus, hypertension and renal disease in England and Wales by country of birth. Health Trends 1997;28:122-7.
17. Cruickshank JK, Beevers DG, Osbourne VL, Haynes RA, Corlett JC, Selby S. Heart attack, stroke, diabetes, and hypertension in West Indians, Asians, and whites in Birmingham, England. BMJ 1980;281:1108.
18. Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and metaanalysis. J Hypertens 2005;23:913-20.
19. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002;325:1271.
20. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004;43:566-72.
21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21.
22. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)-JAMA 2002;288:2981-97.
23. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998;32:820-4.
24. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with once-daily calcium channel blockade or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000;356:366-72.
25. Padmanabhan S, Wallace C, Munroe P, Dobson R, Brown M, Samani N, et al. Chromosome 2p shows genomewide significant linkage to anti-hypertensive medication response in the British genetics of hypertension (BRIGHT) study. Hypertension 2005. (doi:10.1161/01.HYP.0000197947.62601.9d).